PhRMA elects new members of board of directors
Monday, June 22, 2015
The Pharmaceutical Research and Manufacturers of America (PhRMA) has announced the election of five of its newest members to its board of directors.
“Over the past couple of months, we have been pleased to welcome five exceptional leaders to PhRMA’s board,” said John J. Castellani, PhRMA president and CEO. “Our organization will benefit not only from their deep understanding of the economic, regulatory and legislative issues facing our industry, but also from the global perspective, tested leadership and proven industry success they will bring to bear to help guide PhRMA’s work in the coming years.”
PhRMA’s newest board members include:
Werner Baumann is chairman of the board of management of Bayer HealthCare. He also serves as chief strategy and portfolio officer of Bayer, with responsibility for corporate development and mergers and acquisitions. Previously, Baumann was Bayer’s chief financial officer. He has been with the company since 1988, first working in Germany and Spain before assuming leadership roles in the U.S. and once again in Germany.
Giovanni Caforio, M.D., is CEO of Bristol-Myers Squibb. Caforio joined the company in 2000 as vice president and general manager, Italy, in the Worldwide Medicines Group. In 2010, he was named senior vice president, Global Commercialization, Oncology and Immunology, before becoming president of the U.S. business in 2011. Prior to becoming CEO, he was chief operating officer leading a fully integrated worldwide commercial organization and the company-wide functions of Enterprise Services and Global Manufacturing & Supply, and was elected to Bristol-Myers Squibb’s board of directors in 2014.
Peter Greenleaf is CEO of Sucampo Pharmaceuticals, and a member of the company’s board of directors. Before joining Sucampo, Greenleaf was CEO and a board member of Histogenics, a regenerative medicine company, from June 2013 through February 2014. From 2008 to June 2013, Greenleaf was employed by MedImmune, the global biologics arm of AstraZeneca, where he most recently was president and was responsible for driving the expansion of the company’s pipeline and preclinical programs and the commercialization of its marketed products. Greenleaf also was president of MedImmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group, and the company’s previous chief commercial officer.
Ramona Sequeira is president of Takeda Pharmaceutical USA, responsible for the company’s commercial operations in the U.S. Prior to joining Takeda, Sequeira held leadership positions at Eli Lilly, both in the U.S. and U.K. In her role as general manager, Sequeira had responsibility for all affiliate operations in U.K., Republic of Ireland and Northern Europe, and represented the company as a board member of the Association of the British Pharmaceutical Industry.
Timothy P. Walbert is chairman, president and CEO of Horizon Pharma. Before joining the company, Walbert was president, CEO and director of IDM Pharma, a public biopharmaceutical company that was acquired by Takeda America in June 2009. Prior to IDM, he was executive vice president, Commercial Operations at NeoPharm, a public biopharmaceutical company. From 2001 to 2005, Walbert was divisional vice president and general manager, Immunology, at Abbott Laboratories, now AbbVie, where he led the global development and launch of a multi-indication biologic.